Laxmi Dental Ltd (LAXMIDENTL) — shareholding pattern, promoter holding, financials and share price
About Laxmi Dental Ltd (LAXMIDENTL)
Laxmi Dental Ltd operates in the Medical Equipment & Supplies industry, within the Healthcare sector. It trades on the NSE as LAXMIDENTL and on the BSE under scrip code 544339. Its ISIN is INE0WO601020.
Incorporated in 2004, Laxmi Dental is an integrated dental products company offering a comprehensive portfolio of Dental Products [1]
Laxmi Dental Limited is an end‑to‑end integrated dental products and services company that manufactures crowns, bridges, dentures, clear aligners, thermoforming sheets, 3D printing resins, intraoral scanners and paediatric dental products across six manufacturing facilities while selling into 95+ countries and a 22,000+ strong dental network.
Q3FY26 revenue was INR 660.4 million, up 7.1% YoY, while adjusted metrics show pressures: gross margins at 69.5%, EBITDA fell to INR 69.7 million with adjusted EBITDA INR 96.1 million, and the quarter included an exceptional INR 57.8 million labour‑code provision that materially reduced reported PAT and margins.
Listed peers in Medical Equipment & Supplies: Tarsons Products Ltd, Q-Line Biotech Ltd, OSEL Devices Ltd, Fabtech Technologies Ltd, Vasa Denticity Ltd, Hemant Surgical Industries Ltd.
Valuation & Returns
10 Jul 2026At ₹220.35 a share on 10 Jul 2026, Laxmi Dental Ltd (LAXMIDENTL) was valued at a price-to-earnings ratio of 45.81x against an industry P/E of 44.11x and a price-to-book of 5.81x on a book value of ₹37.94 per share as of Mar 2025. Solomo computes return on equity of 12.68% and return on capital employed of 13.29% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 45.81x
- Industry P/E
- 44.11x
- P/B
- 5.81x
- EPS (TTM)
- ₹4.81
- Book value / share
- ₹37.94
- ROE
- 12.68%
- ROCE
- 13.29%
- ROA
- 9.29%
- Debt / equity
- 0.09x
- Dividend yield
- 0%
- EBITDA margin
- 17%
- 52-week range
- ₹155.65 – ₹509.75
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Laxmi Dental Ltd (LAXMIDENTL) reported revenue of ₹278 crore, net profit of ₹29 crore and earnings per share of ₹5.27. That compares with revenue of ₹239 crore and net profit of ₹32 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹74 crore and net profit ₹10 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 137 | 162 | 194 | 239 | 278 |
| Net profit (₹ cr) | -19 | -4 | 25 | 32 | 29 |
| EPS (₹) | -596.62 | -128.94 | 804.81 | 5.78 | 5.27 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 8.77% | 14.94% | 23.53% |
| Profit growth | - | - | 50.98% |
| Stock price CAGR | - | - | -53% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 41.8% of Laxmi Dental Ltd (LAXMIDENTL) (up 0.03 pp QoQ), foreign institutional investors (FII) hold 30.1% and domestic institutional investors (DII) hold 10.89%. Market capitalisation was ₹1,211 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2025.
Largest disclosed public shareholders in Jun 2026: Orbimed Asia Ii Mauritius Limited 22.41%, Icici Prudential Pharma Healthcare And Diaganostics (P.H.D) Fund 4.68%, Goldman Sachs Funds - Goldman Sachs India Equity Portfolio 3.5%, Amrish Desai 2.02%, Parag Jamnadas Bhimjiyani 2.02%, Hdfc Mutual Fund - Hdfc Pharma And Healthcare Fund 1.37%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 41.8% | - | 30.1% | 10.89% | 58.2% |
| Mar 2026 | 41.77% | - | 31.21% | 10.52% | 58.23% |
| Dec 2025 | 41.7% | - | 32.45% | 10.83% | 58.3% |
| Sep 2025 | 41.7% | - | 32.39% | 11.85% | 58.3% |
| Jun 2025 | 41.7% | - | 33.59% | 14.31% | 58.3% |
| Mar 2025 | 41.7% | - | 34.24% | 12.86% | 58.3% |